A new trading day began on Friday, with Terns Pharmaceuticals Inc (NASDAQ: TERN) stock price down -3.02% from the previous day of trading, before settling in for the closing price of $4.64. TERN’s price has ranged from $4.32 to $11.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. Meanwhile, its annual earnings per share averaged 6.27%. With a float of $62.32 million, this company’s outstanding shares have now reached $84.92 million.
Let’s look at the performance matrix of the company that is accounted for 66 employees. In terms of profitability, gross margin is 47.35%, operating margin of -7562.78%, and the pretax margin is -6641.75%.
Terns Pharmaceuticals Inc (TERN) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Terns Pharmaceuticals Inc is 26.63%, while institutional ownership is 71.57%. The most recent insider transaction that took place on Jan 02 ’25, was worth 25,607. In this transaction Chief Medical Officer of this company sold 4,481 shares at a rate of $5.71, taking the stock ownership to the 54,269 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Financial Officer sold 9,059 for $5.80, making the entire transaction worth $52,500. This insider now owns 74,752 shares in total.
Terns Pharmaceuticals Inc (TERN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.53% during the next five years compared to -12.40% drop over the previous five years of trading.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Here are Terns Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 32.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.32 in one year’s time.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Terns Pharmaceuticals Inc (NASDAQ: TERN) saw its 5-day average volume 1.77 million, a positive change from its year-to-date volume of 1.67 million. As of the previous 9 days, the stock’s Stochastic %D was 26.23%. Additionally, its Average True Range was 0.33.
During the past 100 days, Terns Pharmaceuticals Inc’s (TERN) raw stochastic average was set at 1.71%, which indicates a significant decrease from 7.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.36% in the past 14 days, which was lower than the 76.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.87, while its 200-day Moving Average is $6.90. Nevertheless, the first resistance level for the watch stands at $4.62 in the near term. At $4.74, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.83. If the price goes on to break the first support level at $4.42, it is likely to go to the next support level at $4.33. The third support level lies at $4.21 if the price breaches the second support level.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Key Stats
With a market capitalization of 382.22 million, the company has a total of 84,939K Shares Outstanding. Currently, annual sales are 0 K while annual income is -90,210 K. The company’s previous quarter sales were 0 K while its latest quarter income was -21,950 K.
